How effective is Nintedanib?

Nintedanib(Nintedanib)marketed as Ofev and Vargatef is an oral drug used to treat idiopathic pulmonary fibrosis and with other drugs for certain types of non-small cell lung cancer. Nintedanib sold under the trade names Ofev and Vargatef is an oral drug used to treat idiopathic pulmonary fibrosis and with other drugs for certain types of non-small cell lung cancer.

Nintedanib is an intracellular tyrosine kinase inhibitor that inhibits the progression of pulmonary fibrosis. Althoughnintedanibis effective in idiopathic pulmonary fibrosis, its efficacy in various pulmonary fibrotic diseases is unknown.

Methods:In this double-blind, placebo-controlled Phase 3 trial in 15 countries, we randomized high-resolution computed tomography< Patients with fibrotic lung disease whose CT scan showed lung capacity exceeding 10% were treated with nintedanib at 150 mg/d or placebo. All patients met criteria for progression of interstitial lung disease within the past 24months and had a forced vital capacity(FVC)that was at least predicted despite treatment. span>45%, and the diffusing capacity of the lungs for carbon monoxide is 30% to less than 80% of the predicted value. Randomization was stratified according to the pattern of fibrosis on high-resolution CT(a common interstitial pneumonia[UIP]or other fibrosis pattern). The primary endpoint was the annual rate of decline in FVC assessed over 52 weeks. The two main populations used for analysis were the overall population and patients with a UIP-like fibrosis pattern.

Results:A total of663 patients were treated. Across the entire population, adjustedFVC decline rate, nintedanib group was-80.8ml/years, the placebo group was-187.8ml/years, the difference between groups was 10 7.0ml/years(95%confidence interval[CI]is65.4-148.5; P<0.001). In patients with UIPlike fibrosis patterns, the adjusted FVC decline rate was -82.9ml/ years, and -211.1ml/years in the placebo group, a difference of 128.2 ml (95% CI, 70.8-185.6; P<0.001). Diarrhea was the most common adverse event, reported in 66.9% of patients receiving nintedanib and 23.9% of patients receiving placebo. Liver function test abnormalities were more common in the nintedanib group compared with the placebo group.

Conclusion:In patients with progressive fibrotic interstitial lung disease, patients treated with nintedanib had a significantly lower annual rate of decline in FVC than those treated with placebo. IndiaBDRPharmaceutical retail price150mg30tablets400around one hundred, the retail price in pharmacy is around100mg30 tablets400around one hundred. Retail price of Beacon Pharmaceutical in Bangladesh150mg60tablets3000tablets, ASEAN Pharmaceutical in Laos100mg30tabletsabout 6000, 100mg60tabletsabout 7760yuan. The retail price of the Indian original version in pharmacies is about 150 mg 60 tablets 5900 yuan. Patients can choose drug versions based on their financial situation. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.